Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor
Abstract Few treatments have proven effective for patients with chronic spinal cord injury (SCI). This study aimed to evaluate the efficacy and safety of acidic fibroblast growth factor (aFGF) in human SCI. This was an open-label prospective clinical trial of aFGF with an extended follow-up to 48 mo...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2018-08-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-018-31083-4 |
| _version_ | 1819202627994386432 |
|---|---|
| author | Chin-Chu Ko Tsung-Hsi Tu Jau-Ching Wu Wen-Cheng Huang Yun-An Tsai Shih-Fong Huang Hsueh-Chen Huang Henrich Cheng |
| author_facet | Chin-Chu Ko Tsung-Hsi Tu Jau-Ching Wu Wen-Cheng Huang Yun-An Tsai Shih-Fong Huang Hsueh-Chen Huang Henrich Cheng |
| author_sort | Chin-Chu Ko |
| collection | DOAJ |
| description | Abstract Few treatments have proven effective for patients with chronic spinal cord injury (SCI). This study aimed to evaluate the efficacy and safety of acidic fibroblast growth factor (aFGF) in human SCI. This was an open-label prospective clinical trial of aFGF with an extended follow-up to 48 months. All patients were treated with aFGF 3 times, including once directly applied to the injured spinal cord during neurolysis surgery, and twice via lumbar punctures at 3- and 6-months post-operation. Every patient was evaluated with standardized measurements of neurological functions. The trial initially enrolled 60 patients (30 cervical and 30 thoracolumbar SCI), but only 46 (21 cervical- and 25 thoracolumbar-SCI) completed the follow-up. The ASIA impairment scales, motor, pin prick, light touch, and FIM motor subtotal scores were all improved in both groups, except that the ASIA scores of light touch only demonstrated tendency of increase in the cervical-SCI group. All patients had a decrease in dependence, and there were no major adverse events or other oncological problems throughout the follow-up. At 48 months, the study demonstrated that aFGF was safe, feasible, and could yield modest functional improvement in chronic SCI patients. Further randomized control investigations are warranted for validation of its optimal dosage. |
| first_indexed | 2024-12-23T04:07:02Z |
| format | Article |
| id | doaj.art-f178265967004f39aa60c5e1b3e90f18 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-23T04:07:02Z |
| publishDate | 2018-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-f178265967004f39aa60c5e1b3e90f182022-12-21T18:00:36ZengNature PortfolioScientific Reports2045-23222018-08-018111010.1038/s41598-018-31083-4Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factorChin-Chu Ko0Tsung-Hsi Tu1Jau-Ching Wu2Wen-Cheng Huang3Yun-An Tsai4Shih-Fong Huang5Hsueh-Chen Huang6Henrich Cheng7Jhong Jheng Spine & Orthopedic HospitalDepartment of Neurosurgery, Neurological Institute, Taipei Veterans General HospitalDepartment of Neurosurgery, Neurological Institute, Taipei Veterans General HospitalDepartment of Neurosurgery, Neurological Institute, Taipei Veterans General HospitalCenter for Neural Regeneration, Neurological Institute, Taipei Veterans General HospitalCenter for Neural Regeneration, Neurological Institute, Taipei Veterans General HospitalDepartment of Neurosurgery, Neurological Institute, Taipei Veterans General HospitalDepartment of Neurosurgery, Neurological Institute, Taipei Veterans General HospitalAbstract Few treatments have proven effective for patients with chronic spinal cord injury (SCI). This study aimed to evaluate the efficacy and safety of acidic fibroblast growth factor (aFGF) in human SCI. This was an open-label prospective clinical trial of aFGF with an extended follow-up to 48 months. All patients were treated with aFGF 3 times, including once directly applied to the injured spinal cord during neurolysis surgery, and twice via lumbar punctures at 3- and 6-months post-operation. Every patient was evaluated with standardized measurements of neurological functions. The trial initially enrolled 60 patients (30 cervical and 30 thoracolumbar SCI), but only 46 (21 cervical- and 25 thoracolumbar-SCI) completed the follow-up. The ASIA impairment scales, motor, pin prick, light touch, and FIM motor subtotal scores were all improved in both groups, except that the ASIA scores of light touch only demonstrated tendency of increase in the cervical-SCI group. All patients had a decrease in dependence, and there were no major adverse events or other oncological problems throughout the follow-up. At 48 months, the study demonstrated that aFGF was safe, feasible, and could yield modest functional improvement in chronic SCI patients. Further randomized control investigations are warranted for validation of its optimal dosage.https://doi.org/10.1038/s41598-018-31083-4 |
| spellingShingle | Chin-Chu Ko Tsung-Hsi Tu Jau-Ching Wu Wen-Cheng Huang Yun-An Tsai Shih-Fong Huang Hsueh-Chen Huang Henrich Cheng Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor Scientific Reports |
| title | Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor |
| title_full | Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor |
| title_fullStr | Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor |
| title_full_unstemmed | Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor |
| title_short | Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor |
| title_sort | functional improvement in chronic human spinal cord injury four years after acidic fibroblast growth factor |
| url | https://doi.org/10.1038/s41598-018-31083-4 |
| work_keys_str_mv | AT chinchuko functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT tsunghsitu functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT jauchingwu functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT wenchenghuang functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT yunantsai functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT shihfonghuang functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT hsuehchenhuang functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT henrichcheng functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor |